Abstract:Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a global pandemic. Safe and effective vaccination is critical to ending the epidemic of COVID-19. Although randomized clinical trials are considered the “gold standard” for evaluating intervention effects of vaccines, they have notable limitations. As mass vaccination campaigns against COVID-19 commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting. Meanwhile, SARS-CoV-2 variants continue to emerge during the global pandemic and may facilitate escape from current vaccine immune protection. Hence, COVID19 vaccines faced many challenges, such as safety, immunogenicity, and efficacy of the COVID-19 Vaccine in special populations, the duration of protective effectiveness, viral mutations and breakthrough infection, antibody-dependent enhancement effect, and pathogenic autoimmune and so on. This article summarizes these tissues studied at present, it is of great significance for public health and social measures in the ongoing pandemic response.
杨朝国, 杨晶艳, 吴俐莎, 刘继芬, 刘武. COVID-19疫苗保护效力及挑战[J]. 中国人兽共患病学报, 2021, 37(12): 1108-1117.
YANG Chao-guo, YANG Jing-yan, WU Li-sha, LIU Ji-fen, LIU Wu. Protective effectiveness and challenges of COVID-19 vaccines. Chinese Journal of Zoonoses, 2021, 37(12): 1108-1117.
[1] World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines[EB/OL].(2020-08-20)[2021-07-18].https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. [2] 林剑生,沈佳莹,曹广文.SARS-CoV-2 疫苗的种类、机制及临床试验的效果[J/OL].上海预防医学. (2021-09-16)[2021-09-20].https://kns.cnki.net/kcms/detail/31.1635.R.20210915.1455.002.Html. [3] 黄苏玥,沈银忠. 新型冠状病毒疫苗的研发进展[J].上海医药,2021,42(17):16-21. [4] Dagan N, Barda N, Kepten E, et al.BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting[J]. New Engl J Med,2021,384:1412-1423. DOI:10.1056/NEJMoa2101765 [5] Wang RK, Zhang Q, Ge JW, et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species[J/OL]. Immunity. (2021-06-04)[2021-09-20]. DOI: 10.1016/j.immuni.2021.06.003 [6] World Health Organization, Tracking SARS-CoV-2 variants[EB/OL]. (2021-09-17)[2021-07-20]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ [7] Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data[J]. Lancet, 2021,397:1819-1829. DOI:10.1016/S0140-6736 (21)00947-8 [8] Thompson MG, Burgess JL, Naleway AL, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders,other essential and frontline workers — eight U.S. locations, December2020-March 2021[J]. MMWR, 2021,70:495-500.https://www.medscape.com/viewarticle/948658. [9] Abu-Raddad LJ, Chemaitelly H,Butt AA, Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants[J/OL]. New Engl J Med. (2021-05-05)[2021-07-20]. DOI:10.1056/NEJMc2104974 [10] Dolgin E,CureVac COVID vaccine let-down spotlights mRNA design challenges[J/OL]. Nature. (2021-06-18)[2021-07-20]. DOI:10.1038/d41586-021-01661-0 [11] Polack FP, Thomas SJ, Kitchin N, et al.Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine[J]. New Engl J Med, 2020,383(27):2603-2615. DOI: 10.1056/NEJMoa2034577 [12] Baden LR, El Sahly HM, Essink B, et al.Efficacy and safety of the mRNA-1273SARS-CoV-2 vaccine[J]. New Engl J Med, 2021, 384(5):403-416. DOI: 10.1056/NEJMoa2035389 [13] Jara A, Undurraga EA, Gonzalez C,et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile[J/OL]. New Engl J Med. (2021-07-07)[2021-07-20]. DOI: 10.1056/NEJMoa 2107715 [14] Tanriover MD, Doĝanay HL, Akova M, et al . Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey[J/OL]. Lancet. (2021-07-08)[2021-07-20]. DOI:10.1016/ S0140-6736(21)01429-X [15] Moutinho S,Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil[J/OL]. Science. (2021-04-09)[2021-07-20]. DOI:10.1126/science.abi9414 [16] Jeewandara C, Aberathna IS, Pushpakumara PD,et al. Antibody and T cell responses to Sinopharm/BBIBP-CorV in naīve and previously infected individuals in Sri Lanka[EB/OL]. (2021-07-19)[2021-07-20]. DOI:10.1101/2021.07.15.21260621 [17] Schenkelberg T,Vaccine-induced protection in aging adults and pandemic response[J]. Biochem Bioph Res Co, 2021,538: 218-220. DOI:10.1016/j.bbrc.2020.10.090 [18] Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2[J/OL]. Nature. (2021-06-30)[2021-07-20]. DOI:10.1038/s41586-021-03739-1 [19] Pellini R, Venuti A,Pimpinelli F,et al.Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine[J]. E Clin Med, 2021,36: 100928. DOI:10.1016/j.eclinm.2021.100928 [20] Wall EC, Wu M, Harvey R,et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination[J/OL]. Lancet. (2021-06-03)[2021-07-20]. DOI:10.1016/ S0140-6736(21)01290-3 [21] Ferenci T, Sarkadi B, Virus neutralizing antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine[EB/OL].(2021-07-19)[2021-07-20]. DOI:10.1101/2021.07.15.21260362 [22] Parry H, Bruton R, Stephens C, et al.Extended interval BNT162b2 vaccination enhances peak antibody generation in older people[EB/OL].medRxiv preprint. DOI:10.1101/2021.05.15.21257017 [23] Sun L, Warner JL, Parikh RB, Immune responses to SARS-CoV-2 among patients with cancer what can seropositivity tell us[J/OL]. JAMA Oncol. (2021-05-28)[2021-07-20]. DOI:10.1001/jamaoncol.2021.2096 [24] Yazaki. S, Tatsuya Yoshida Y, Kojima Y, et al. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan[J/OL].JAMA Oncol. (2021-05-28)[2021-07-20]. DOI:10.1001/jamaoncol.2021.2159 [25] Massarweh A,Eliakim-Raz N,Amos Stemmer A, et al.Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer[J/OL]. JAMA Oncol. (2021-05-28)[2021-07-20]. DOI:10.1001/jamaoncol.2021.2155 [26] Palich R, Veyri M, Marot S, et al.Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients[J/OL]. JAMA Oncol. (2021-04-20)[2021-07-20]. DOI:10.1016/j.annonc.2021.04.020 [27] Gray KJ, Bordt EA, Atyeo C, et al.Coronavirus disease2019 vaccine response in pregnant and lactating women: a cohort study[J/OL]. Am J Obstet Gynecol.(2021-05-23)[2021-07-20]. DOI:10.1016/j.ajog.2021.03.023 [28] Mo MH, Wang M, Wang MM,et al.Detectable antibodies against SARS-CoV-2 in newborns from mothers infected with COVID-19 at different gestational ages[J]. Pediatrics Neonatol,2021,62:321-323. DOI:10.1016/j.pedneo.2021.03.011 [29] Shimabukuro TT, KimSY, Myers TR,et al. Preliminary Findings of mRNA Covid-19Vaccine Safety in Pregnant Persons[J/OL]. New Engl J Med. (2021-04-21)[2021-07-20]. DOI: 10.1056/NEJMoa2104983 [30] Frenck RW, Klein NP, Kitchin N, et al. Safety, Immunogenicity,efficacy of the BNT162b2 Covid-19 vaccine in adolescents[J/OL]. New Engl J Med. (2021-05-27)[2021-07-20]. DOI: 10.1056/NEJMoa2107456 [31] Han BH, Song YF, Li CG,et al. Safety, tolerability,immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial[J/OL]. Lancet Infect Dis. (2021-06-28)[2021-07-20]. DOI:10.1016/ S1473-3099(21)00319-4 [32] Chia WN, Zhu F, Ong SWX, et al.Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study[J]. Lancet Microbe, 2021, 2: e240-249. DOI:10.1016/ S2666-5247(21)00025-2 [33] Radbruch A, Hyun-Dong Chang HD, A long-term perspective on immunity to COVID[J/OL]. Nature. (2021-06-14)[2021-07-20]. DOI:10.1038/d41586-021-01557-z [34] Turner JS,Kim W,Kalaidina E,et al.SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans[J/OL].Nature. (2021-05-24)[2021-07-20]. DOI:10.1038/s41586-021-03647-4 [35] Wang, Z,Muecksch F,Schaefer-Babajew D, et al.Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection[J/OL].Nature. (2021-06-14)[2021-07-20]. DOI:10.1038/s41586-021-03696-9 (2021) [36] 杨朝国,刘继芬,蒋宏, COVID-19 疫苗免疫应答及保护效力研究进展[J].中国公共卫生,2021,37(5):896-901. DOI:10.11847/zgggws1134410 [37] Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants[J/OL]. Nature. (2021-06-10)[2021-07-20]. DOI:10.1038/s41586-021-03693-y [38] Huang BY, Dai LP, Wang H, et al. Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2[J/OL]. Lancet Microbe. (2021-04-13)[2021-07-20]. DOI:10.1016/ S2666-5247(21)00082-3 [39] Geers D, Shamier MC, Bogers S,et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccines[J/OL].Sci Imminol. (2021-05-25)[2021-07-20]. DOI: 10.1126/sciimmunol.abj1750 [40] Ferreira I, Datir R, Kemp S,et al. SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies[EB/OL]. (2021-05-18)[2021-07-20]. BioRxiv. DOI: 10.1101/2021.05.08.443253 [41] Hoffmann M,Hofmann-Winkler H,Krüge N,et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination[EB/OL].(2021-05-05)[2021-07-20]. BioRxiv. DOI:10.1101/2021.05.04.442663 [42] Hacisuleyman E, Caryn Hale C, Yuhki Saito Y, et al.Vaccine breakthrough infections with SARS-CoV-2 variants[J]. New Engl J Med,2021, 384:2212-2218.DOI: 10.1056/NEJMoa2105000 [43] Fonseca V, de Jesus R, Adelino T,et al. Genomic evidence of SARS-CoV-2 reinfection case with the emerging B.1.2 variant in Brazil[J/OL]. J Infect. (2021-05-20)[2021-07-20]. DOI:10.1016/j.jinf.2021.05.014 [44] Vitale J, Mumoli N, Clerici P,et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in lombardy, Italy[J/OL]. JAMA Int Med,(2021-05-28)[2021-07-20]. DOI:10.1001/jamainternmed.2021.2959 [45] Hall VJ, Foulkes S, Charlett A,et al.SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England:a large, multicentre, prospective cohort study (SIREN)[J]. Lancet,2021,397:1459-1469. DOI:10.1016/S0140-6736(21)00675-9 [46] Brinkley Rubinstein L, Peterson M, Martin R, et al.Breakthrough SARS-CoV-2 Infections in Prison after Vaccination[J/OL]. New Engl J Med. (2021-07-07)[2021-07-20]. DOI: 10.1056/NEJMc2108479 [47] Li BS, Deng AP, Li KB,et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant[EB/OL]. (2021-07-23)[2021-07-25]. DOI:10.1101/2021.07.07.21260122 [48] Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization[J/OL]. Nature.(2021-07-08)[2021-07-25]. DOI:10.1038/s41586-021-03777-9 [49] Jamie Lopez Bernal FFPH, Andrews N, Gower C,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant[J/OL]. New Engl J Med. (2021-07-21)[2021-07-25].DOI: 10.1056/NEJMoa2108891 [50] Voss WN, Hou YJ, Johnson NV, et al. Prevalent, protective,convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes[J].Science,2021,372(6546):11086546):1108-1112. http://science.sciencemag.org/content/372/6546/1108. [51] Cerutti G, Guo YC, Zhou TQ,et al.Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite[J]. Cell Host Microbe,2021, 29:819-833.DOI:10.1016/j.chom.2021.03.005 [52] Suryadevara N, Shrihari S, Gilchuk P, et al.Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein[J]. Cell, 2021,184: 2316-2331.DOI:10.1016/j.cell.2021.03.029 [53] Liu YF, Soh WT, Kishikawa JI,et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies[J/OL]. Cell. (2021-05-24)[2021-07-20]. DOI:10.1016/j.cell.2021.05.032 [54] Cines DB, Bussel JB,SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia[J]. New Engl J Med,2021,384:2254-2256. DOI:10.1056/NEJMe2106315 [55] Huynh A, Kelton JG, Arnold DM, et al. Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia[J/OL]. Nature. (2021-07-07)[2021-07-20]. DOI:10.1038/s41586-021-03744-4 [56] Scully M, Singh D, Lown R, et al.Pathologic antibodies to platelet factor 4after ChAdOx1 nCoV-19 vaccination[J]. New Engl J Med, 2021,384:2202-2211. DOI: 10.1056/NEJMoa2105385